CClinicalTrials.gg
Sign In
Status unknownNCT01917370iccUpdated Aug 6, 2013

VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway

An observational study in Intrahepatic Cholangiocarcinoma, sponsored by First Affiliated Hospital, Sun Yat-Sen University. Status unknown at 1 site in China. Open to participants aged 16 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-08-06.

Sponsored by First Affiliated Hospital, Sun Yat-Sen University · Observational

The sponsor has not verified this record recently (last verified Aug 2013), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Ages
16 Years to 90 Years
Sex
All
01

Study summary

The investigators study the VEGF signaling in ICC cell lines／human tissues and its mechanism in HCC growth, proliferation and apoptosis.

Read the detailed description

Several studies have documented the elevated expression of VEGF and its receptors in ICC cell lines and tumor tissues. Another study observed that the elevation of VEGF promotes the growth. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in ICC cells and its possible mechanism in regulating ICC growth.Therefore,we try to clarify the mechanism of VEGF signal in ICC growth,proliferation and apoptosis.

02

Conditions studied

  • Intrahepatic Cholangiocarcinoma

Browse trials for

Keywords

  • intrahepatic cholangiocarcinoma
  • icc
  • vegf signal pathway
03

In context

Cholangiocarcinoma

913 studies on the registry are indexed under Cholangiocarcinoma; 285 are open to participants now.

This study's planned enrollment of 20 is below the median of 196 across 176 observational studies indexed under Cholangiocarcinoma.

Browse Cholangiocarcinoma studies →

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 155 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

intrahepatic cholangiocarcinoma patients underwent surgical therapy

Inclusion criteria

  1. hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of intrahepatic cholangiocarcinoma and CA199>100U/L；or two or more dynamic imagine with a diagnosis of intrahepatic cholangiocarcinoma
  2. Child-Pugh A or B
  3. well preserved renal and hematopoietic Function
  4. receive complete surgical therapy
  5. achieve complete section accessed by contrast-enhanced CT

Exclusion criteria

Exclusion Criteria:

  1. incomplete section
  2. Child-Pugh C
  3. combination with other hepatobiliary disease
  4. suffer from other tumors concurrently or in last five years
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ICC patients

    patients with intrahepatic cholangiocarcinoma treated by surgical treatment

    Procedure: surgical treatment

Interventions

  • Proceduresurgical treatment

    all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.

    Also known as: hepatectomy

06

What researchers measure

Primary outcomes

  1. the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.

    the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).

    Time frame: the day when conducting surgery (day 1)

07

Study locations

1 site
  • First Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01917370
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Collaborators
Guangdong Province, Department of Science and Technology
Responsible party
Ming Kuang,MD,PhD (MD,PhD, First Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Aug 6, 2013
Start date
Oct 2012
Primary completion
Dec 2013 (estimated)
Completion
Dec 2014 (estimated)
Last update
Aug 6, 2013

Study contacts

Ming Kuang, MD
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cholangiocarcinoma→

Other studies from this sponsor

First Affiliated Hospital, Sun Yat-Sen University

Start the discussion